AI Article Synopsis
- Overactive bladder is characterized by urgency, frequent urination, and nocturia, typically treated with sacral neuromodulation (SNM) and intravesical botulinum toxin (BTX) after conservative methods fail.
- A review of six studies (648 participants) found that both SNM and BTX are effective, with no significant complications.
- SNM is more successful after BTX fails, leading to greater patient satisfaction compared to using BTX after SNM unsuccessful.*
Article Abstract
Background: Overactive bladder is a syndrome of urgency with the absence of infection and is usually accompanied by frequency and nocturia. Both sacral neuromodulation (SNM) and intravesical botulinum toxin (BTX) injection are used contentiously in overactive bladder after failure of conservative management.
Objective: We aimed to provide an updated comparative overview of BTX injection versus SNM in the treatment of overactive bladder.
Methods: PubMed and Google scholar databases were explored starting from 2016 to 2022 to obtain relevant articles. English studies on adult population were included.
Results: Six articles included 648 participants were included in the current overview. Both BTX and SNM are comparable for the treatment of overactive bladder, with no major complications were reported. However, the use of SNM for refractory overactive bladder after failure of BTX was more successful and effective and resulted in patient satisfaction compared to the use of BTX after failure of SNM.
Conclusion: Our update provides the latest comparative overview of outcomes of BTX versus SNM in the treatment of overactive bladder.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019876 | PMC |
| http://dx.doi.org/10.5455/medarh.2022.76.469-472 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!